BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Santhanam P, Russell J, Rooper LM, Ladenson PW, Pomper MG, Rowe SP. The prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer. Med Oncol 2020;37:98. [PMID: 33034761 DOI: 10.1007/s12032-020-01427-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Rizzo A, Dall'Armellina S, Pizzuto DA, Perotti G, Zagaria L, Lanni V, Treglia G, Racca M, Annunziata S. PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor? Cancers (Basel) 2022;14:4039. [PMID: 36011032 DOI: 10.3390/cancers14164039] [Reference Citation Analysis]
2 Wiggins RH, Hoffman JM, Fine GC, Covington MF, Salem AE, Koppula BR, Morton KA. PET-CT in Clinical Adult Oncology-V. Head and Neck and Neuro Oncology. Cancers (Basel) 2022;14:2726. [PMID: 35681709 DOI: 10.3390/cancers14112726] [Reference Citation Analysis]
3 Zampella E, Klain M, Pace L, Cuocolo A. PET/CT in the management of differentiated thyroid cancer. Diagn Interv Imaging 2021;102:515-23. [PMID: 33926848 DOI: 10.1016/j.diii.2021.04.004] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
4 Santhanam P, Cooper DS. How Should We Approach Incidental Thyroid Nodules with Gallium-68 Prostate-Specific Membrane Antigen (PSMA) Positivity? Clinical Thyroidology 2021;33:87-91. [DOI: 10.1089/ct.2021;33.87-91] [Reference Citation Analysis]